Jacques Simard

List of Publications by Year in Descending Order

345 papers	21,029 citations	70 h-index	133 g-index
362 ext. papers	24,857 ext. citations	8.1 avg, IF	5.54 L-index

#	Paper	IF	Citations
345	Rare germline copy number variants (CNVs) and breast cancer risk.. *Communications Biology*, **2022**, 5, 65	6.7	0
344	Common variants in breast cancer risk loci predispose to distinct tumor subtypes.. *Breast Cancer Research*, **2022**, 24, 2	8.3	3
343	Women's perceptions of PERSPECTIVE: a breast cancer risk stratification e-platform.. *Hereditary Cancer in Clinical Practice*, **2022**, 20, 8	2.3	0
342	A Genome-Wide Gene-Based Gene-Environment Interaction Study of Breast Cancer in More than 90,000 Women. *Cancer Research Communications*, **2022**, 2, 211-219		0
341	Prospective evaluation of a breast-cancer risk model integrating classical risk factors and polygenic risk in 15 cohorts from six countries. *International Journal of Epidemiology*, **2021**,	7.8	6
340	A Collaborative Model to Implement Flexible, Accessible and Efficient Oncogenetic Services for Hereditary Breast and Ovarian Cancer: The C-MOnGene Study. *Cancers*, **2021**, 13,	6.6	1
339	Evaluation of the association of heterozygous germline variants in NTHL1 with breast cancer predisposition: an international multi-center study of 47,180 subjects. *Npj Breast Cancer*, **2021**, 7, 52	7.8	2
338	Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer. *Human Genetics and Genomics Advances*, **2021**, 2, 100042-100042	0.8	2
337	Personalized Risk Assessment for Prevention and Early Detection of Breast Cancer: Integration and Implementation (PERSPECTIVE I&I). *Journal of Personalized Medicine*, **2021**, 11,	3.6	13
336	The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. *Genetics in Medicine*, **2021**, 23, 1726-1737	8.1	2
335	Risk-Stratified Approach to Breast Cancer Screening in Canada: Women's Knowledge of the Legislative Context and Concerns about Discrimination from Genetic and Other Predictive Health Data. *Journal of Personalized Medicine*, **2021**, 11,	3.6	1
334	Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element. *American Journal of Human Genetics*, **2021**, 108, 1190-1203	11	1
333	PALB2 Variants: Protein Domains and Cancer Susceptibility. *Trends in Cancer*, **2021**, 7, 188-197	12.5	1
332	Personalizing Breast Cancer Screening Based on Polygenic Risk and Family History. *Journal of the National Cancer Institute*, **2021**, 113, 434-442	9.7	10
331	CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers. *British Journal of Cancer*, **2021**, 124, 842-854	8.7	2
330	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. *Nature Communications*, **2021**, 12, 1078	17.4	4
329	Women's Views on Multifactorial Breast Cancer Risk Assessment and Risk-Stratified Screening: A Population-Based Survey from Four Provinces in Canada. *Journal of Personalized Medicine*, **2021**, 11,	3.6	4

328	Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. *New England Journal of Medicine*, **2021**, 384, 428-439	59.2	143
327	Potential of polygenic risk scores for improving population estimates of women's breast cancer genetic risks. *Genetics in Medicine*, **2021**, 23, 2114-2121	8.1	3
326	Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study. *American Journal of Obstetrics and Gynecology*, **2021**, 225, 51.e1-51.e17	6.4	9
325	Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores. *Journal of the National Cancer Institute*, **2021**,	9.7	3
324	Mendelian randomisation study of smoking exposure in relation to breast cancer risk. *British Journal of Cancer*, **2021**, 125, 1135-1145	8.7	0
323	Should Age-Dependent Absolute Risk Thresholds Be Used for Risk Stratification in Risk-Stratified Breast Cancer Screening?. *Journal of Personalized Medicine*, **2021**, 11,	3.6	3
322	Polygenic risk scores for prediction of breast cancer risk in Asian populations.. *Genetics in Medicine*, **2021**,	8.1	2
321	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. *Nature Genetics*, **2020**, 52, 572-581	36.3	76
320	Personalized early detection and prevention of breast cancer: ENVISION consensus statement. *Nature Reviews Clinical Oncology*, **2020**, 17, 687-705	19.4	64
319	Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. *Scientific Reports*, **2020**, 10, 9688	4.9	2
318	Identification of novel breast cancer susceptibility loci in meta-analyses conducted among Asian and European descendants. *Nature Communications*, **2020**, 11, 1217	17.4	16
317	Sequence kernel association test for survival outcomes in the presence of a non-susceptible fraction. *Biostatistics*, **2020**, 21, 518-530	3.7	1
316	Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). *JAMA Oncology*, **2020**, 6, 1218-1230	13.4	25
315	Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers. *Nature Communications*, **2020**, 11, 3353	17.4	32
314	Transcriptome-wide association study of breast cancer risk by estrogen-receptor status. *Genetic Epidemiology*, **2020**, 44, 442-468	2.6	9
313	Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for and Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium. *Cancer Epidemiology Biomarkers and Prevention*, **2020**, 29, 368-378	4	9
312	A network analysis to identify mediators of germline-driven differences in breast cancer prognosis. *Nature Communications*, **2020**, 11, 312	17.4	20
311	Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers. *Breast Cancer Research*, **2020**, 22, 8	8.3	22

310	Association of Genomic Domains in and with Prostate Cancer Risk and Aggressiveness. *Cancer Research*, **2020**, 80, 624-638	10.1	22
309	Functional characterization of 84 PALB2 variants of uncertain significance. *Genetics in Medicine*, **2020**, 22, 622-632	8.1	20
308	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. *Nature Genetics*, **2020**, 52, 56-73	36.3	56
307	A Mendelian randomization analysis of circulating lipid traits and breast cancer risk. *International Journal of Epidemiology*, **2020**, 49, 1117-1131	7.8	17
306	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. *Genetics in Medicine*, **2020**, 22, 1653-1666	8.1	34
305	European polygenic risk score for prediction of breast cancer shows similar performance in Asian women. *Nature Communications*, **2020**, 11, 3833	17.4	31
304	Association of germline variation with the survival of women with pathogenic variants and breast cancer. *Npj Breast Cancer*, **2020**, 6, 44	7.8	3
303	Genetically Predicted Levels of DNA Methylation Biomarkers and Breast Cancer Risk: Data From 228 951 Women of European Descent. *Journal of the National Cancer Institute*, **2020**, 112, 295-304	9.7	18
302	Evaluation of associations between genetically predicted circulating protein biomarkers and breast cancer risk. *International Journal of Cancer*, **2020**, 146, 2130-2138	7.5	9
301	Re-evaluating genetic variants identified in candidate gene studies of breast cancer risk using data from nearly 280,000 women of Asian and European ancestry. *EBioMedicine*, **2019**, 48, 203-211	8.8	9
300	Two truncating variants in FANCC and breast cancer risk. *Scientific Reports*, **2019**, 9, 12524	4.9	2
299	Shared heritability and functional enrichment across six solid cancers. *Nature Communications*, **2019**, 10, 431	17.4	45
298	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. *British Journal of Cancer*, **2019**, 121, 180-192	8.7	13
297	AuthorsMesponse: Associations of obesity and circulating insulin and glucose with breast cancer risk. *International Journal of Epidemiology*, **2019**, 48, 1016-1017	7.8	
296	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. *Nature Communications*, **2019**, 10, 1741	17.4	47
295	Functional Analysis of Promoter Variants in Genes Involved in Sex Steroid Action, DNA Repair and Cell Cycle Control. *Genes*, **2019**, 10,	4.2	6
294	Health professionalsMperspectives on breast cancer risk stratification: understanding evaluation of risk versus screening for disease. *Public Health Reviews*, **2019**, 40, 2	4.3	12
293	Body mass index and the association between low-density lipoprotein cholesterol as predicted by HMGCR genetic variants and breast cancer risk. *International Journal of Epidemiology*, **2019**, 48, 1727-1730	7.8	1

292	Genome-wide association study of germline variants and breast cancer-specific mortality. *British Journal of Cancer*, **2019**, 120, 647-657	8.7	28
291	The association between weight at birth and breast cancer risk revisited using Mendelian randomisation. *European Journal of Epidemiology*, **2019**, 34, 591-600	12.1	11
290	DSNetwork: An Integrative Approach to Visualize Predictions of VariantsMDeleteriousness. *Frontiers in Genetics*, **2019**, 10, 1349	4.5	3
289	The :p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. *Npj Breast Cancer*, **2019**, 5, 38	7.8	12
288	Envisioning Implementation of a Personalized Approach in Breast Cancer Screening Programs: Stakeholder Perspectives. *Healthcare Policy*, **2019**, 15, 39-54	1.1	7
287	A response to "Personalised medicine and population health: breast and ovarian cancer". *Human Genetics*, **2019**, 138, 287-289	6.3	13
286	A global functional analysis of missense mutations reveals two major hotspots in the PALB2 tumor suppressor. *Nucleic Acids Research*, **2019**, 47, 10662-10677	20.1	22
285	Functional analysis of genetic variants in the high-risk breast cancer susceptibility gene PALB2. *Nature Communications*, **2019**, 10, 5296	17.4	21
284	Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort. *International Journal of Cancer*, **2019**, 144, 1195-1204	7.5	18
283	The Tumor Suppressor PALB2: Inside Out. *Trends in Biochemical Sciences*, **2019**, 44, 226-240	10.3	56
282	BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors. *Genetics in Medicine*, **2019**, 21, 1708-1718	8.1	192
281	Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. *Journal of the National Cancer Institute*, **2019**, 111, 350-364	9.7	22
280	Organizational challenges to equity in the delivery of services within a new personalized risk-based approach to breast cancer screening. *New Genetics and Society*, **2019**, 38, 38-59	1.9	6
279	Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis. *International Journal of Epidemiology*, **2019**, 48, 795-806	7.8	52
278	Disentangling the determinants of interest and willingness-to-pay for breast cancer susceptibility testing in the general population: a cross-sectional Web-based survey among women of QuBec (Canada). *BMJ Open*, **2018**, 8, e016662	3	5
277	Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. *Human Mutation*, **2018**, 39, 593-620	4.7	138
276	Inherited mutations in and in an unselected multiethnic cohort of Asian patients with breast cancer and healthy controls from Malaysia. *Journal of Medical Genetics*, **2018**, 55, 97-103	5.8	24
275	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. *Cancer Research*, **2018**, 78, 5419-5430	10.1	32

274	A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. *Nature Genetics*, **2018**, 50, 968-978	36.3	101
273	The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With or Mutations. *JNCI Cancer Spectrum*, **2018**, 2, pky078	4.6	10
272	Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study. *JNCI Cancer Spectrum*, **2018**, 2, pky023	4.6	13
271	Differential Burden of Rare and Common Variants on Tumor Characteristics, Survival, and Mode of Detection in Breast Cancer. *Cancer Research*, **2018**, 78, 6329-6338	10.1	13
270	A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation. *EMBO Molecular Medicine*, **2018**, 10,	12	85
269	Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. *JAMA - Journal of the American Medical Association*, **2017**, 317, 2402-2416	27.4	1140
268	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. *Nature Genetics*, **2017**, 49, 680-691	36.3	190
267	Association analysis identifies 65 new breast cancer risk loci. *Nature*, **2017**, 551, 92-94	50.4	643
266	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. *Nature Genetics*, **2017**, 49, 1767-1778	36.3	186
265	Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. *Journal of Clinical Oncology*, **2017**, 35, 2240-2250	2.2	101
264	Gene-environment interactions involving functional variants: Results from the Breast Cancer Association Consortium. *International Journal of Cancer*, **2017**, 141, 1830-1840	7.5	13
263	Increased Use of BRCA Mutation Test in Unaffected Women Over the Period 2004-2014 in the U.S.: Further Evidence of the "Angelina Jolie Effect"?. *American Journal of Preventive Medicine*, **2017**, 53, e195-e196	6.1	5
262	VEXOR: an integrative environment for prioritization of functional variants in fine-mapping analysis. *Bioinformatics*, **2017**, 33, 1389-1391	7.2	2
261	Inherited Chromosomally Integrated Human Herpesvirus 6 and Breast Cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2017**, 26, 425-427	4	4
260	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. *Breast Cancer Research and Treatment*, **2017**, 161, 117-134	4.4	15
259	Do women change their breast cancer mammogram screening behaviour after BRCA1/2 testing?. *Familial Cancer*, **2017**, 16, 35-40	3	4
258	The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers. *Cancer Epidemiology Biomarkers and Prevention*, **2017**, 26, 126-135	4	183
257	Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. *Journal of the National Cancer Institute*, **2017**, 109,	9.7	153

256	Breast Cancer Risk Estimation and Personal Insurance: A Qualitative Study Presenting Perspectives from Canadian Patients and Decision Makers. *Frontiers in Genetics*, **2017**, 8, 128	4.5	13
255	Transcriptional signature of lymphoblastoid cell lines of , and non- high risk breast cancer families. *Oncotarget*, **2017**, 8, 78691-78712	3.3	6
254	- a novel candidate breast cancer susceptibility locus on 6q14.1. *Oncotarget*, **2017**, 8, 102769-102782	3.3	3
253	The knowledge value-chain of genetic counseling for breast cancer: an empirical assessment of prediction and communication processes. *Familial Cancer*, **2016**, 15, 1-17	3	7
252	An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression. *Human Molecular Genetics*, **2016**, 25, 3863-3876	5.6	24
251	rs2735383, located at a microRNA binding site in the 3′UTR of NBS1, is not associated with breast cancer risk. *Scientific Reports*, **2016**, 6, 36874	4.9	2
250	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. *Cancer Discovery*, **2016**, 6, 1052-67	24.4	104
249	Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. *Breast Cancer Research*, **2016**, 18, 112	8.3	25
248	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. *Nature Communications*, **2016**, 7, 11375	17.4	64
247	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. *Nature Communications*, **2016**, 7, 12675	17.4	53
246	Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs). *Scientific Reports*, **2016**, 6, 32512	4.9	16
245	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. *Nature Genetics*, **2016**, 48, 374-86	36.3	93
244	Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium. *Human Genetics*, **2016**, 135, 137-54	6.3	6
243	BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. *Journal of the National Cancer Institute*, **2016**, 108,	9.7	65
242	RAD51B in Familial Breast Cancer. *PLoS ONE*, **2016**, 11, e0153788	3.7	18
241	Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21. *Oncotarget*, **2016**, 7, 80140-80163	3.3	21
240	Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent. *PLoS Medicine*, **2016**, 13, e1002105	11.6	80
239	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. *PLoS ONE*, **2016**, 11, e0158801	3.7	7

238	ABRAXAS (FAM175A) and Breast Cancer Susceptibility: No Evidence of Association in the Breast Cancer Family Registry. *PLoS ONE*, **2016**, 11, e0156820	3.7	3
237	Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus. *PLoS ONE*, **2016**, 11, e0160316	3.7	11
236	Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer. *International Journal of Cancer*, **2016**, 139, 1303-1317	7.5	26
235	PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. *Journal of Medical Genetics*, **2016**, 53, 800-811	5.8	121
234	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. *Breast Cancer Research*, **2016**, 18, 64	8.3	25
233	Prediction of breast cancer risk based on common genetic variants in women of East Asian ancestry. *Breast Cancer Research*, **2016**, 18, 124	8.3	34
232	Clinical follow-up and breast and ovarian cancer screening of true BRCA1/2 noncarriers: a qualitative investigation. *Genetics in Medicine*, **2016**, 18, 627-34	8.1	4
231	Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model. *Genetics in Medicine*, **2016**, 18, 1190-1198	8.1	64
230	Genetic predisposition to ductal carcinoma in situ of the breast. *Breast Cancer Research*, **2016**, 18, 22	8.3	31
229	Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry. *Cancer Causes and Control*, **2016**, 27, 679-93	2.8	15
228	Usefulness of Canadian Public Health Insurance Administrative Databases to Assess Breast and Ovarian Cancer Screening Imaging Technologies for BRCA1/2 Mutation Carriers. *Canadian Association of Radiologists Journal*, **2016**, 67, 308-312	3.9	3
227	Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation. *American Journal of Human Genetics*, **2016**, 99, 903-911	11	43
226	Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer. *Carcinogenesis*, **2015**, 36, 256-71	4.6	12
225	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. *Nature Genetics*, **2015**, 47, 164-71	36.3	177
224	Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. *Nature Genetics*, **2015**, 47, 373-80	36.3	406
223	Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression. *American Journal of Human Genetics*, **2015**, 97, 22-34	11	26
222	Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. *JAMA - Journal of the American Medical Association*, **2015**, 313, 1347-61	27.4	286
221	Novel Associations between Common Breast Cancer Susceptibility Variants and Risk-Predicting Mammographic Density Measures. *Cancer Research*, **2015**, 75, 2457-67	10.1	45

220	Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair. *Nature Genetics*, **2015**, 47, 1294-1303	36.3	226
219	Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans. *Human Molecular Genetics*, **2015**, 24, 5589-602	5.6	54
218	Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization. *Journal of the National Cancer Institute*, **2015**, 107,	9.7	74
217	Fine-scale mapping of the 4q24 locus identifies two independent loci associated with breast cancer risk. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 1680-91	4	17
216	Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. *Human Molecular Genetics*, **2015**, 24, 285-98	5.6	35
215	Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 308-16	4	20
214	SNP Set Association Testing for Survival Outcomes in the Presence of Intrafamilial Correlation. *Genetic Epidemiology*, **2015**, 39, 406-14	2.6	5
213	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. *Breast Cancer Research*, **2015**, 17, 61	8.3	16
212	Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers. *PLoS ONE*, **2015**, 10, e0120020	3.7	26
211	SNP-SNP interaction analysis of NF-B signaling pathway on breast cancer survival. *Oncotarget*, **2015**, 6, 37979-94	3.3	19
210	Prediction of breast cancer risk based on profiling with common genetic variants. *Journal of the National Cancer Institute*, **2015**, 107,	9.7	324
209	Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. *Human Molecular Genetics*, **2015**, 24, 2966-84	5.6	36
208	Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1. *American Journal of Human Genetics*, **2015**, 96, 5-20	11	59
207	A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium. *Human Molecular Genetics*, **2014**, 23, 1934-46	5.6	28
206	Identification of new genetic susceptibility loci for breast cancer through consideration of gene-environment interactions. *Genetic Epidemiology*, **2014**, 38, 84-93	2.6	24
205	Life insurance: genomic stratification and risk classification. *European Journal of Human Genetics*, **2014**, 22, 575-9	5.3	31
204	Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. *Nature Communications*, **2014**, 4, 4999	17.4	87
203	Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade. *Human Molecular Genetics*, **2014**, 23, 6034-46	5.6	11

202	Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study. *Breast Cancer Research*, **2014**, 16, R51	8.3	12
201	MicroRNA related polymorphisms and breast cancer risk. *PLoS ONE*, **2014**, 9, e109973	3.7	37
200	Medical genetic counseling for breast cancer in primary care: a synthesis of major determinants of physiciansMpractices in primary care settings. *Public Health Genomics*, **2014**, 17, 190-208	1.9	10
199	Genetic predisposition to in situ and invasive lobular carcinoma of the breast. *PLoS Genetics*, **2014**, 10, e1004285	6	38
198	DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. *PLoS Genetics*, **2014**, 10, e1004256	6	33
197	Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium. *Human Molecular Genetics*, **2014**, 23, 6096-111	5.6	48
196	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. *Breast Cancer Research*, **2014**, 16, 3416	8.3	46
195	COMPLEXO: identifying the missing heritability of breast cancer via next generation collaboration. *Breast Cancer Research*, **2013**, 15, 402	8.3	30
194	Family communication following BRCA1/2 genetic testing: a close look at the process. *Journal of Genetic Counseling*, **2013**, 22, 323-35	2.5	21
193	Life events may contribute to family communication about cancer risk following BRCA1/2 testing. *Journal of Genetic Counseling*, **2013**, 22, 249-57	2.5	12
192	Genetic discrimination and life insurance: a systematic review of the evidence. *BMC Medicine*, **2013**, 11, 25	11.4	78
191	Exploring resources for intrafamilial communication of cancer genetic risk: we still need to talk. *European Journal of Human Genetics*, **2013**, 21, 903-10	5.3	13
190	Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. *American Journal of Human Genetics*, **2013**, 93, 1046-60	11	80
189	Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. *Journal of Clinical Oncology*, **2013**, 31, 3091-9	2.2	118
188	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. *Nature Genetics*, **2013**, 45, 371-84, 384e1-2	36.3	422
187	Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. *American Journal of Human Genetics*, **2013**, 92, 489-503	11	167
186	Genome-wide association studies identify four ER negative-specific breast cancer risk loci. *Nature Genetics*, **2013**, 45, 392-8, 398e1-2	36.3	327
185	Large-scale genotyping identifies 41 new loci associated with breast cancer risk. *Nature Genetics*, **2013**, 45, 353-61, 361e1-2	36.3	813

184	A focus group study on breast cancer risk presentation: one format does not fit all. *European Journal of Human Genetics*, **2013**, 21, 719-24	5.3	14
183	Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. *PLoS Genetics*, **2013**, 9, e1003173	6	90
182	Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. *PLoS Genetics*, **2013**, 9, e1003212	6	209
181	Personalized medicine and access to health care: potential for inequitable access?. *European Journal of Human Genetics*, **2013**, 21, 143-7	5.3	33
180	Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. *Breast Cancer Research*, **2012**, 14, R33	8.3	70
179	Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. *Human Mutation*, **2012**, 33, 690-702	4.7	31
178	Self-reported mammography use following BRCA1/2 genetic testing may be overestimated. *Familial Cancer*, **2012**, 11, 27-32	3	8
177	Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriers. *Breast Cancer Research and Treatment*, **2012**, 136, 295-302	4.4	3
176	Influence of the family cluster effect on psychosocial variables in families undergoing BRCA1/2 genetic testing for cancer susceptibility. *Psycho-Oncology*, **2012**, 21, 515-23	3.9	5
175	Functional analysis of promoter variants in KU70 and their role in cancer susceptibility. *Genes Chromosomes and Cancer*, **2012**, 51, 1007-13	5	6
174	A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 1362-70	4	20
173	Incidence and predictors of positive and negative effects of BRCA1/2 genetic testing on familial relationships: a 3-year follow-up study. *Genetics in Medicine*, **2012**, 14, 60-8	8.1	7
172	Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 645-57	4	44
171	Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 134-47	4	411
170	Effectiveness of risk-reducing salpingo-oophorectomy in preventing ovarian cancer in a high-risk French Canadian population. *International Journal of Gynecological Cancer*, **2012**, 22, 974-8	3.5	9
169	Systematic mixed-methods reviews are not ready to be assessed with the available tools. *Journal of Clinical Epidemiology*, **2011**, 64, 926-8	5.7	7
168	Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. *Breast Cancer Research*, **2011**, 13, R110	8.3	62
167	Return of research results: general principles and international perspectives. *Journal of Law, Medicine and Ethics*, **2011**, 39, 583-92	1.2	23

166	Breast and ovarian cancer screening of non-carriers from BRCA1/2 mutation-positive families: 2-year follow-up of cohorts from France and Quebec. *European Journal of Human Genetics*, **2011**, 19, 494-9	5.3	14
165	The CYP17A1 -34T > C polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers. *Breast Cancer Research and Treatment*, **2011**, 126, 521-7	4.4	3
164	Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. *Human Molecular Genetics*, **2011**, 20, 3304-21	5.6	62
163	Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. *Human Molecular Genetics*, **2011**, 20, 4732-47	5.6	21
162	Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. *Journal of the National Cancer Institute*, **2011**, 103, 105-16	9.7	37
161	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. *Nature Genetics*, **2010**, 42, 885-92	36.3	276
160	Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. *Cancer Research*, **2010**, 70, 9742-54	10.1	147
159	Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2010**, 19, 2859-68	4	32
158	Evaluation of the contribution of the three breast cancer susceptibility genes CHEK2, STK11, and PALB2 in non-BRCA1/2 French Canadian families with high risk of breast cancer. *Genetic Testing and Molecular Biomarkers*, **2010**, 14, 515-26	1.6	23
157	Pooled analysis indicates that the GSTT1 deletion, GSTM1 deletion, and GSTP1 Ile105Val polymorphisms do not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers. *Breast Cancer Research and Treatment*, **2010**, 122, 281-5	4.4	5
156	Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. *Human Molecular Genetics*, **2009**, 18, 4442-56	5.6	91
155	Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study. *Cancer Epidemiology Biomarkers and Prevention*, **2009**, 18, 601-10	4	110
154	No association of TGFB1 L10P genotypes and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a multi-center cohort study. *Breast Cancer Research and Treatment*, **2009**, 115, 185-92	4.4	11
153	Analysis of 17beta-hydroxysteroid dehydrogenase types 5, 7, and 12 genetic sequence variants in breast cancer cases from French Canadian Families with high risk of breast and ovarian cancer. *Journal of Steroid Biochemistry and Molecular Biology*, **2009**, 116, 134-53	5.1	11
152	Characterization of HSD17B1 sequence variants in breast cancer cases from French Canadian families with high risk of breast and ovarian cancer. *Journal of Steroid Biochemistry and Molecular Biology*, **2008**, 109, 115-28	5.1	6
151	Mutation analysis and characterization of HSD17B2 sequence variants in breast cancer cases from French Canadian families with high risk of breast and ovarian cancer. *Journal of Molecular Endocrinology*, **2008**, 40, 161-72	4.5	11
150	Health behaviors and psychological distress in women initiating BRCA1/2 genetic testing: comparison with control population. *Journal of Genetic Counseling*, **2008**, 17, 314-26	2.5	31
149	Analysis of GADD45A sequence variations in French Canadian families with high risk of breast cancer. *Journal of Human Genetics*, **2008**, 53, 490-498	4.3	7

148	Mutational analysis of the breast cancer susceptibility gene BRIP1 /BACH1/FANCJ in high-risk non-BRCA1/BRCA2 breast cancer families. *Journal of Human Genetics*, **2008**, 53, 579	4.3	33
147	Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. *American Journal of Human Genetics*, **2008**, 82, 937-48	11	218
146	Genetic sequence variations and ADPRT haplotype analysis in French Canadian families with high risk of breast cancer. *Journal of Human Genetics*, **2007**, 52, 963-977	4.3	10
145	Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer. *Journal of Medical Genetics*, **2007**, 44, 107-21	5.8	58
144	AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study. *Cancer Epidemiology Biomarkers and Prevention*, **2007**, 16, 1416-21	4	26
143	Clinical management recommendations for surveillance and risk-reduction strategies for hereditary breast and ovarian cancer among individuals carrying a deleterious BRCA1 or BRCA2 mutation. *Journal of Obstetrics and Gynaecology Canada*, **2007**, 29, 45-60	1.3	33
142	Factors associated with an individualM decision to withdraw from genetic testing for breast and ovarian cancer susceptibility: implications for counseling. *Genetic Testing and Molecular Biomarkers*, **2007**, 11, 45-54		37
141	Effect of the WomenM Health Initiative study publication on hormone replacement therapy use among women who have undergone BRCA1/2 testing. *Cancer Epidemiology Biomarkers and Prevention*, **2007**, 16, 157-60	4	5
140	RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. *American Journal of Human Genetics*, **2007**, 81, 1186-200	11	204
139	Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families. *BMC Cancer*, **2006**, 6, 230	4.8	38
138	Using the impact of event scale to evaluate distress in the context of genetic testing for breast cancer susceptibility. *Psychological Reports*, **2006**, 98, 873-81	1.6	3
137	The AIB1 polyglutamine repeat does not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2006**, 15, 76-9	4	24
136	Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS CollaboratorsM Group. *Journal of Clinical Oncology*, **2006**, 24, 3361-6	2.2	150
135	No Evidence of BRCA1/2 genomic rearrangements in high-risk French-Canadian breast/ovarian cancer families. *Genetic Testing and Molecular Biomarkers*, **2006**, 10, 104-15		43
134	BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families. *Breast Cancer Research*, **2006**, 8, R3	8.3	64
133	Use of dietary supplements among women at high risk of hereditary breast and ovarian cancer (HBOC) tested for cancer susceptibility. *Nutrition and Cancer*, **2006**, 54, 157-65	2.8	12
132	Pooled genome linkage scan of aggressive prostate cancer: results from the International Consortium for Prostate Cancer Genetics. *Human Genetics*, **2006**, 120, 471-85	6.3	55
131	The emergence of an ethical duty to disclose genetic research results: international perspectives. *European Journal of Human Genetics*, **2006**, 14, 1170-8	5.3	221

130	Partnering in oncogenetic research--the INHERIT BRCAs experience: opportunities and challenges. *Familial Cancer*, **2006**, 5, 3-13	3	11
129	A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. *American Journal of Human Genetics*, **2005**, 77, 219-29	11	129
128	Synthesis and structure-activity relationships of analogs of EM-652 (acolbifene), a pure selective estrogen receptor modulator. Study of nitrogen substitution. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2005**, 20, 165-77	5.6	15
127	Characterization of the guinea pig 3beta-hydroxysteroid dehydrogenase/Delta5-Delta4-isomerase expressed in the adrenal gland and gonads. *Journal of Steroid Biochemistry and Molecular Biology*, **2005**, 97, 289-98	5.1	3
126	Molecular biology of the 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase gene family. *Endocrine Reviews*, **2005**, 26, 525-82	27.2	408
125	CYP17 and breast cancer: no overall effect, but what about interactions?. *Breast Cancer Research*, **2005**, 7, 238-42	8.3	11
124	HRT use among women tested for BRCA1/2 mutations following publication of the women's health initiative study results. *Journal of Obstetrics and Gynaecology Canada*, **2005**, 27, 321; author reply 322	1.3	1
123	A new alternative splice variant of BRCA1 containing an additional in-frame exon. *Biochimica Et Biophysica Acta Gene Regulatory Mechanisms*, **2005**, 1731, 57-65		11
122	Molecular and genealogical characterization of the R1443X BRCA1 mutation in high-risk French-Canadian breast/ovarian cancer families. *Human Genetics*, **2005**, 117, 119-32	6.3	44
121	Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. *Endocrine Reviews*, **2005**, 26, 361-79	27.2	125
120	Macrophage scavenger receptor 1 999C>T (R293X) mutation and risk of prostate cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2005**, 14, 397-402	4	17
119	GATA factors and the nuclear receptors, steroidogenic factor 1/liver receptor homolog 1, are key mutual partners in the regulation of the human 3beta-hydroxysteroid dehydrogenase type 2 promoter. *Molecular Endocrinology*, **2005**, 19, 2358-70		78
118	17alpha-hydroxylase/17,20-Lyase deficiency due to novel compound heterozygote mutations: treatment for tall stature in a female with male pseudohermaphroditism and spontaneous puberty in her affected sister. *Journal of Pediatric Endocrinology and Metabolism*, **2005**, 18, 403-11	1.6	9
117	No evidence of false reassurance among women with an inconclusive BRCA1/2 genetic test result. *Cancer Epidemiology Biomarkers and Prevention*, **2005**, 14, 2862-7	4	41
116	Are ATM mutations 7271T-->G and IVS10-6T-->G really high-risk breast cancer-susceptibility alleles?. *Cancer Research*, **2004**, 64, 840-3	10.1	44
115	Structure of primate and rodent orthologs of the prostate cancer susceptibility gene ELAC2. *Biochimica Et Biophysica Acta Gene Regulatory Mechanisms*, **2004**, 1679, 230-47		10
114	Changes in health-related behaviours following BRCA 1/2 genetic testing: the case of hormone replacement therapy. *Journal of Obstetrics and Gynaecology Canada*, **2004**, 26, 1059-66	1.3	8
113	Results of a genome-wide linkage analysis in prostate cancer families ascertained through the ACTANE consortium. *Prostate*, **2003**, 57, 270-9	4.2	37

112	Characterization and modulation of sex steroid metabolizing activity in normal human keratinocytes in primary culture and HaCaT cells. *Journal of Steroid Biochemistry and Molecular Biology*, **2003**, 87, 167-79	5.1	23
111	Characterization of a novel mutation causing hepatic lipase deficiency among French Canadians. *Journal of Lipid Research*, **2003**, 44, 1508-14	6.3	24
110	Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. *Endocrine Reviews*, **2003**, 24, 152-82	27.2	445
109	Genomic organization and expression of the mouse Brca2 gene. *Mammalian Genome*, **2002**, 13, 352-8	3.2	3
108	Synergistic action of prolactin (PRL) and androgen on PRL-inducible protein gene expression in human breast cancer cells: a unique model for functional cooperation between signal transducer and activator of transcription-5 and androgen receptor. *Molecular Endocrinology*, **2002**, 16, 1696-710		32
107	Congenital adrenal hyperplasia due to 3beta-hydroxysteroid dehydrogenase/Delta(5)-Delta(4) isomerase deficiency. *Seminars in Reproductive Medicine*, **2002**, 20, 255-76	1.4	51
106	Perspective: prostate cancer susceptibility genes. *Endocrinology*, **2002**, 143, 2029-40	4.8	37
105	Glucocorticoids enhance activation of the human type II 3beta-hydroxysteroid dehydrogenase/Delta5-Delta4 isomerase gene. *Journal of Steroid Biochemistry and Molecular Biology*, **2002**, 82, 55-63	5.1	26
104	DHEA and its transformation into androgens and estrogens in peripheral target tissues: intracrinology. *Frontiers in Neuroendocrinology*, **2001**, 22, 185-212	8.9	267
103	A candidate prostate cancer susceptibility gene at chromosome 17p. *Nature Genetics*, **2001**, 27, 172-80	36.3	469
102	Pure selective estrogen receptor modulators, new molecules having absolute cell specificity ranging from pure antiestrogenic to complete estrogen-like activities. *Advances in Protein Chemistry*, **2001**, 56, 293-368		13
101	Crucial role of cytokines in sex steroid formation in normal and tumoral tissues. *Molecular and Cellular Endocrinology*, **2001**, 171, 25-40	4.4	38
100	Multiple signal transduction pathways mediate interleukin-4-induced 3beta-hydroxysteroid dehydrogenase/Delta5-Delta4 isomerase in normal and tumoral target tissues. *Journal of Steroid Biochemistry and Molecular Biology*, **2001**, 76, 213-25	5.1	20
99	EM-652 (SCH57068), a pure SERM having complete antiestrogenic activity in the mammary gland and endometrium. *Journal of Steroid Biochemistry and Molecular Biology*, **2001**, 79, 213-25	5.1	40
98	Multiple signaling pathways mediate interleukin-4-induced 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase type 1 gene expression in human breast cancer cells. *Molecular Endocrinology*, **2000**, 14, 229-40		21
97	A novel A10E homozygous mutation in the HSD3B2 gene causing severe salt-wasting 3beta-hydroxysteroid dehydrogenase deficiency in 46,XX and 46,XY French-Canadians: evaluation of gonadal function after puberty. *Journal of Clinical Endocrinology and Metabolism*, **2000**, 85, 1968-74	5.6	30
96	A new insight into the molecular basis of 3beta-hydroxysteroid dehydrogenase deficiency. *Endocrine Research*, **2000**, 26, 761-70	1.9	16
95	Role of 17 beta-hydroxysteroid dehydrogenases in sex steroid formation in peripheral intracrine tissues. *Trends in Endocrinology and Metabolism*, **2000**, 11, 421-7	8.8	109

94	Induction of 3beta-hydroxysteroid dehydrogenase/isomerase type 1 expression by interleukin-4 in human normal prostate epithelial cells, immortalized keratinocytes, colon, and cervix cancer cell lines. *Endocrinology*, **1999**, 140, 4573-84	4.8	51
93	Induction of 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase type 1 gene transcription in human breast cancer cell lines and in normal mammary epithelial cells by interleukin-4 and interleukin-13. *Molecular Endocrinology*, **1999**, 13, 66-81		63
92	Parallel solid-phase synthesis of a model library of 7alpha-alkylamide estradiol derivatives as potential estrogen receptor antagonists. *Bioorganic and Medicinal Chemistry Letters*, **1999**, 9, 2827-32	2.9	21
91	EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium. *Journal of Steroid Biochemistry and Molecular Biology*, **1999**, 69, 51-84	5.1	149
90	New insight into the molecular basis of 3beta-hydroxysteroid dehydrogenase deficiency: identification of eight mutations in the HSD3B2 gene eleven patients from seven new families and comparison of the functional properties of twenty-five mutant enzymes. *Journal of Clinical Endocrinology and Metabolism*, **1999**, 84, 4410-25	5.6	77
89	Fine mapping of low-density lipoprotein receptor gene by genetic linkage on chromosome 19p13.1-p13.3 and study of the founder effect of four French Canadian low-density lipoprotein receptor gene mutations. *Atherosclerosis*, **1999**, 143, 145-51	3.1	20
88	BRCA1 gene expression in reproductive and endocrine tissues in adult cynomolgus monkey. *Annals of the New York Academy of Sciences*, **1998**, 839, 444-6	6.5	
87	Identification of three mutations in the low-density lipoprotein receptor gene causing familial hypercholesterolemia among French Canadians. *Human Mutation*, **1998**, Suppl 1, S226-31	4.7	24
86	Regulation of sex steroid formation by interleukin-4 and interleukin-6 in breast cancer cells. *Journal of Steroid Biochemistry and Molecular Biology*, **1998**, 65, 151-62	5.1	28
85	DHEA and the intracrine formation of androgens and estrogens in peripheral target tissues: its role during aging. *Steroids*, **1998**, 63, 322-8	2.8	301
84	Linkage analysis of chromosome 1q markers in 136 prostate cancer families. The Cancer Research Campaign/British Prostate Group U.K. Familial Prostate Cancer Study Collaborators. *American Journal of Human Genetics*, **1998**, 62, 653-8	11	112
83	Association of specific LDL receptor gene mutations with differential plasma lipoprotein response to simvastatin in young French Canadians with heterozygous familial hypercholesterolemia. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **1998**, 18, 1007-12	9.4	71
82	Genetic linkage mapping of the CYP11A1 gene encoding the cholesterol side-chain cleavage P450scc close to the CYP1A1 gene and D15S204 in the chromosome 15q22.33-q23 region. *Pharmacogenetics and Genomics*, **1998**, 8, 49-53		14
81	Localization of BRCA1 gene expression in adult cynomolgus monkey tissues. *Journal of Histochemistry and Cytochemistry*, **1997**, 45, 1173-88	3.4	8
80	(S)-(+)-4-[7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl)-ethoxy]phenyl]-2H-1-benzopyran-3-yl]-phenyl 2,2-dimethylpropanoate (EM-800): a highly potent, specific, and orally active nonsteroidal antiestrogen. *Journal of Medicinal Chemistry*, **1997**, 40, 2117-22	8.3	131
79	Comparison of in vitro effects of the pure antiandrogens OH-flutamide, Casodex, and nilutamide on androgen-sensitive parameters. *Urology*, **1997**, 49, 580-6; discussion 586-9	1.6	35
78	The key role of 17 beta-hydroxysteroid dehydrogenases in sex steroid biology. *Steroids*, **1997**, 62, 148-58	2.8	418
77	Structure-function relationships of 3 beta-hydroxysteroid dehydrogenase: contribution made by the molecular genetics of 3 beta-hydroxysteroid dehydrogenase deficiency. *Steroids*, **1997**, 62, 176-84	2.8	61

76	Molecular cloning, upstream sequence and promoter studies of the human gene for the regulatory subunit RII alpha of cAMP-dependent protein kinase. *Biochimica Et Biophysica Acta Gene Regulatory Mechanisms*, **1997**, 1350, 98-108		15
75	Characterization of the effects of the novel non-steroidal antiestrogen EM-800 on basal and estrogen-induced proliferation of T-47D, ZR-75-1 and MCF-7 human breast cancer cells in vitro. *International Journal of Cancer*, **1997**, 73, 104-12	7.5	53
74	Interleukin-4 and interleukin-13 inhibit estrogen-induced breast cancer cell proliferation and stimulate GCDFP-15 expression in human breast cancer cells. *Molecular and Cellular Endocrinology*, **1996**, 121, 11-8	4.4	48
73	Generation of an integrated transcription map of the BRCA2 region on chromosome 13q12-q13. *Genomics*, **1996**, 36, 86-99	4.3	34
72	BRCA2 germline mutations in male breast cancer cases and breast cancer families. *Nature Genetics*, **1996**, 13, 123-5	36.3	289
71	Localization and regulation of expression of the FAR-17A gene in the hamster flank organs. *Journal of Investigative Dermatology*, **1996**, 107, 44-50	4.3	8
70	Linkage analysis of 26 Canadian breast and breast-ovarian cancer families. *Human Genetics*, **1995**, 95, 545-50	6.3	24
69	The human type II 17 beta-hydroxysteroid dehydrogenase gene encodes two alternatively spliced mRNA species. *DNA and Cell Biology*, **1995**, 14, 849-61	3.6	61
68	Local and systemic reduction by topical finasteride or flutamide of hamster flank organ size and enzyme activity. *Journal of Investigative Dermatology*, **1995**, 105, 678-82	4.3	33
67	Identification and characterization of the G15D mutation found in a male patient with 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD) deficiency: alteration of the putative NAD-binding domain of type II 3 beta-HSD. *Biochemistry*, **1995**, 34, 2893-900	3.2	31
66	Mapping of the HSD17B2 gene encoding type II 17 beta-hydroxysteroid dehydrogenase close to D16S422 on chromosome 16q24.1-q24.2. *Genomics*, **1995**, 25, 724-6	4.3	24
65	Generation of a transcription map at the HSD17B locus centromeric to BRCA1 at 17q21. *Genomics*, **1995**, 28, 530-42	4.3	39
64	Genetic linkage mapping of the dehydroepiandrosterone sulfotransferase (STD) gene on the chromosome 19q13.3 region. *Genomics*, **1995**, 29, 781-3	4.3	11
63	DHEA and peripheral androgen and estrogen formation: intracinology. *Annals of the New York Academy of Sciences*, **1995**, 774, 16-28	6.5	218
62	Structure-function relationships and molecular genetics of the 3 beta-hydroxysteroid dehydrogenase gene family. *Journal of Steroid Biochemistry and Molecular Biology*, **1995**, 55, 489-505	5.1	25
61	Molecular basis of human 3 beta-hydroxysteroid dehydrogenase deficiency. *Journal of Steroid Biochemistry and Molecular Biology*, **1995**, 53, 127-38	5.1	66
60	Rapid restriction fragment analysis for screening four point mutations of the low-density lipoprotein receptor gene in French Canadians. *Human Mutation*, **1995**, 6, 243-6	4.7	24
59	Interleukin-6 inhibits the potent stimulatory action of androgens, glucocorticoids and interleukin-1 alpha on apolipoprotein D and GCDFP-15 expression in human breast cancer cells. *International Journal of Cancer*, **1995**, 62, 732-7	7.5	36

58	The gene for hereditary breast-ovarian cancer, BRCA1, maps distal to EDH17B2 in chromosome region 17q12-q21. *Human Molecular Genetics*, **1994**, 3, 1679-82	5.6	18
57	Functional characterization of the novel L108W and P186L mutations detected in the type II 3 beta-hydroxysteroid dehydrogenase gene of a male pseudohermaphrodite with congenital adrenal hyperplasia. *Human Molecular Genetics*, **1994**, 3, 1639-45	5.6	33
56	Detection of a novel mutation (stop 468) in exon 10 of the low-density lipoprotein receptor gene causing familial hypercholesterolemia among French Canadians. *Human Molecular Genetics*, **1994**, 3, 1689-91	5.6	33
55	Opposite effects of prolactin and corticosterone on the expression and activity of 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase in rat skin. *Journal of Investigative Dermatology*, **1994**, 103, 60-4	4.3	8
54	Congenital adrenal hyperplasia caused by a novel homozygous frameshift mutation 273 delta AA in type II 3 beta-hydroxysteroid dehydrogenase gene (HSD3B2) in three male patients of Afghan/Pakistani origin. *Human Molecular Genetics*, **1994**, 3, 327-30	5.6	33
53	Potent stimulatory effect of interleukin-1 alpha on apolipoprotein D and gross cystic disease fluid protein-15 expression in human breast-cancer cells. *International Journal of Cancer*, **1994**, 59, 400-7	7.5	36
52	Synthesis and antiestrogenic activity of diaryl thioether derivatives. *Journal of Medicinal Chemistry*, **1994**, 37, 1115-25	8.3	33
51	Inverse relationships between cell proliferation and basal or androgen-stimulated apolipoprotein D secretion in LNCaP human prostate cancer cells. *Journal of Steroid Biochemistry and Molecular Biology*, **1994**, 51, 167-74	5.1	37
50	Rapid modulation of ovarian 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase gene expression by prolactin and human chorionic gonadotropin in the hypophysectomized rat. *Molecular and Cellular Endocrinology*, **1994**, 99, 63-71	4.4	35
49	Formation and degradation of dihydrotestosterone by recombinant members of the rat 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase family. *Molecular and Cellular Endocrinology*, **1994**, 103, 29-38	4.4	8
48	Structure, regulation and role of 3 beta-hydroxysteroid dehydrogenase, 17 beta-hydroxysteroid dehydrogenase and aromatase enzymes in the formation of sex steroids in classical and peripheral intracrine tissues. *Baillière's Clinical Endocrinology and Metabolism*, **1994**, 8, 451-74		55
47	Genetic mapping of the breast-ovarian cancer syndrome to a small interval on chromosome 17q12-21: exclusion of candidate genes EDH17B2 and RARA. *Human Molecular Genetics*, **1993**, 2, 1193-9	5.6	61
46	Detection of polymorphisms in the estradiol 17 beta-hydroxysteroid dehydrogenase II gene at the EDH17B2 locus on 17q11-q21. *Human Molecular Genetics*, **1993**, 2, 479-83	5.6	32
45	Combination therapy for prostate cancer. Endocrine and biologic basis of its choice as new standard first-line therapy. *Cancer*, **1993**, 71, 1059-67	6.4	67
44	Mapping of the regulatory subunits RI beta and RII beta of cAMP-dependent protein kinase genes on human chromosome 7. *Genomics*, **1992**, 14, 63-9	4.3	19
43	Congenital adrenal hyperplasia due to point mutations in the type II 3 beta-hydroxysteroid dehydrogenase gene. *Nature Genetics*, **1992**, 1, 239-45	36.3	199
42	Assignment of the gene encoding the catalytic subunit C beta of cAMP-dependent protein kinase to the p36 band on chromosome 1. *Human Genetics*, **1992**, 88, 653-7	6.3	10
41	Detection of frequent BglII polymorphism by polymerase chain reaction and TaqI restriction fragment length polymorphism for 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase at the human HSD beta 3 locus (1p11-p13). *Human Genetics*, **1991**, 87, 753-4	6.3	12

40	Structure and expression of a new complementary DNA encoding the almost exclusive 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase in human adrenals and gonads. *Molecular Endocrinology*, **1991**, 5, 1147-57		313
39	Ontogenesis of 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase in the rat adrenal as revealed by immunocytochemistry and in situ hybridization. *Endocrinology*, **1991**, 129, 2687-92	4.8	24
38	Localization of peripheral benzodiazepine binding sites and diazepam-binding inhibitor (DBI) mRNA in mammary glands and dimethylbenz(a)antracene (DMBA)-induced mammary tumors in the rat. *Regulatory Peptides*, **1991**, 33, 263-73		18
37	Characterization of macaque 3 beta-hydroxy-5-ene steroid dehydrogenase/delta 5-delta 4 isomerase: structure and expression in steroidogenic and peripheral tissues in primate. *Molecular and Cellular Endocrinology*, **1991**, 75, 101-10	4.4	59
36	Dopaminergic regulation of pre-proNPY mRNA levels in the rat arcuate nucleus. *Neuroscience Letters*, **1991**, 127, 96-8	3.3	31
35	Structure of two in tandem human 17 beta-hydroxysteroid dehydrogenase genes. *Molecular Endocrinology*, **1990**, 4, 268-75		171
34	Multihormonal control of pre-pro-somatostatin mRNA levels in the periventricular nucleus of the male and female rat hypothalamus. *Neuroendocrinology*, **1990**, 52, 527-36	5.6	38
33	Structure and sexual dimorphic expression of a liver-specific rat 3 beta-hydroxysteroid dehydrogenase/isomerase. *Endocrinology*, **1990**, 127, 3237-9	4.8	83
32	Regulation of progesterone-binding breast cyst protein GCDFP-24 secretion by estrogens and androgens in human breast cancer cells: a new marker of steroid action in breast cancer. *Endocrinology*, **1990**, 126, 3223-31	4.8	96
31	Localization of the endogenous benzodiazepine ligand octadecaneuropeptide in the rat testis. *Endocrinology*, **1990**, 127, 1986-94	4.8	41
30	Regulation of 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase expression and activity in the hypophysectomized rat ovary: interactions between the stimulatory effect of human chorionic gonadotropin and the luteolytic effect of prolactin. *Endocrinology*, **1990**, 127, 2726-37	4.8	50
29	Localization of 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase in rat gonads and adrenal glands by immunocytochemistry and in situ hybridization. *Endocrinology*, **1990**, 127, 1394-403	4.8	63
28	Opposite effects of estrogen and the progestin R5020 on cell proliferation and GCDFP-15 expression in ZR-75-1 human breast cancer cells. *Molecular and Cellular Endocrinology*, **1990**, 73, 171-8	4.4	13
27	Potent antagonism between estrogens and androgens on GCDFP-15 expression and cell growth in the ZR-75-1 human breast cancer cells. *Annals of the New York Academy of Sciences*, **1990**, 586, 174-87	6.5	7
26	Purification, cloning, complementary DNA structure, and predicted amino acid sequence of human estradiol 17 beta-dehydrogenase. *Annals of the New York Academy of Sciences*, **1990**, 595, 40-52	6.5	22
25	Interactions between estrogens, androgens, progestins, and glucocorticoids in ZR-75-1 human breast cancer cells. *Annals of the New York Academy of Sciences*, **1990**, 595, 130-48	6.5	22
24	Synthetic progestins stimulate prostatic binding protein messenger RNAs in the rat ventral prostate. *Molecular and Cellular Endocrinology*, **1990**, 68, 169-79	4.4	28
23	Down-regulation of estrogen receptors by androgens in the ZR-75-1 human breast cancer cell line. *Endocrinology*, **1989**, 125, 392-9	4.8	93

22	Stimulation of androgen-dependent gene expression by the adrenal precursors dehydroepiandrosterone and androstenedione in the rat ventral prostate. *Endocrinology*, **1989**, 124, 2745-54	4.8	75
21	Regulation of pro-gonadotropin-releasing hormone gene expression by sex steroids in the brain of male and female rats. *Molecular Endocrinology*, **1989**, 3, 1748-56		86
20	Inhibitory effect of estrogens on GCDFP-15 mRNA levels and secretion in ZR-75-1 human breast cancer cells. *Molecular Endocrinology*, **1989**, 3, 694-702		50
19	Characterization of cDNAs for human estradiol 17 beta-dehydrogenase and assignment of the gene to chromosome 17: evidence of two mRNA species with distinct 5' termini in human placenta. *Molecular Endocrinology*, **1989**, 3, 1301-9		262
18	Characterization of two mRNA species encoding human estradiol 17 beta-dehydrogenase and assignment of the gene to chromosome 17. *The Journal of Steroid Biochemistry*, **1989**, 34, 189-97		20
17	Antagonism between estrogens and androgens on GCDFP-15 gene expression in ZR-75-1 cells and correlation between GCDFP-15 and estrogen as well as progesterone receptor expression in human breast cancer. *The Journal of Steroid Biochemistry*, **1989**, 34, 397-402		18
16	Molecular cloning, cDNA structure and predicted amino acid sequence of bovine 3 beta-hydroxy-5-ene steroid dehydrogenase/delta 5-delta 4 isomerase. *FEBS Letters*, **1989**, 259, 153-7	3.8	64
15	Inhibitory effect of androgen on estrogen-induced prolactin messenger ribonucleic acid accumulation in the male rat anterior pituitary gland. *Endocrinology*, **1989**, 125, 1821-8	4.8	36
14	Full oestrogenic activity of C19-delta 5 adrenal steroids in rat pituitary lactotrophs and somatotrophs. *Molecular and Cellular Endocrinology*, **1988**, 55, 233-42	4.4	34
13	Effect of luteinizing hormone releasing hormone (LHRH) and [D-Trp6, des-Gly-NH2(10)]LHRH ethylamide on alpha-subunit and LH beta messenger ribonucleic acid levels in rat anterior pituitary cells in culture. *Molecular Endocrinology*, **1988**, 2, 521-7		23
12	Modulation by sex steroids and [D-Trp6, Des-Gly-NH2(10)]luteinizing hormone (LH)-releasing hormone ethylamide of alpha-subunit and LH beta messenger ribonucleic acid levels in the rat anterior pituitary gland. *Molecular Endocrinology*, **1988**, 2, 775-84		25
11	Multiple factors controlling ACTH secretion at the anterior pituitary level. *Annals of the New York Academy of Sciences*, **1987**, 512, 97-114	6.5	19
10	Adrenal C19-5-ene steroids induce full estrogenic responses in rat pituitary gonadotrophs. *The Journal of Steroid Biochemistry*, **1987**, 26, 539-46		19
9	Somatostatin prevents the desensitizing action of growth hormone-releasing factor on growth hormone release. *Peptides*, **1987**, 8, 199-205	3.8	20
8	Combination therapy in stage C and D prostatic cancer: rationale and five year clinical experience. *Cancer and Metastasis Reviews*, **1987**, 6, 615-36	9.6	6
7	Stimulation of growth hormone release and synthesis by estrogens in rat anterior pituitary cells in culture. *Endocrinology*, **1986**, 119, 2004-11	4.8	80
6	Characteristics of the desensitization of growth hormone and cyclic AMP responses to growth hormone-releasing factor and prostaglandin E2 in rat anterior pituitary cells in culture. *Molecular and Cellular Endocrinology*, **1986**, 46, 79-89	4.4	11
5	Regulation of growth hormone mRNA and pro-opiomelanocortin mRNA levels by cyclic AMP in rat anterior pituitary cells in culture. *DNA and Cell Biology*, **1986**, 5, 263-70		31

4	Atrial natriuretic factor-induced cGMP accumulation in rat anterior pituitary cells in culture is not coupled to hormonal secretion. *Regulatory Peptides*, **1986**, 15, 269-78		21
3	Keoxifene shows pure antiestrogenic activity in pituitary gonadotrophs. *Molecular and Cellular Endocrinology*, **1985**, 39, 141-4	4.4	28
2	Enhancing the BOADICEA cancer risk prediction model to incorporate new data on RAD51C, RAD51D, BARD1, updates to tumour pathology and cancer incidences		1
1	Common variants in breast cancer risk loci predispose to distinct tumor subtypes		1